United States Securities and Exchange Commission
Washington, DC 20549
--------------------------------------------------------------------------------
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2004
-----------------------------
Provectus Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Nevada 0-9410 90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of (Commission (I.R.S. Employer
Incorporation or Organization) File Number) Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: 865/769-4011
---------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events
On July 28, 2004, Provectus Pharmaceuticals, Inc. announced that it had
received a $20.75 million financial commitment from Cornell Capital Partners,
LP. A copy of the entire press release is incorporated herein by reference and
attached to this report as an exhibit.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press Release dated July 29, 2004
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Provectus Pharmaceuticals, Inc.
Dated: July 28, 2004 By: /s/ H. Craig Dees
---------------------------------
H. Craig Dees, Ph.D.
Chief Executive Officer